Skip to main navigation Skip to search Skip to main content

Pharmacodynamic profile of carvedilol

  • P. A. van Zwieten*
  • *Corresponding author for this work
  • University of Amsterdam

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The combination of a beta blocker and a vasodilator is logical in the treatment of high blood pressure. Systemic arteriolar dilatation is beneficial to reduce the elevated peripheral resistance and hence to decrease cardiac afterload. β-Adrenoceptor blockade exerts its own antihypertensive activity and also suppresses the reflex tachycardia induced by vasodilatation. The combined β- and α-adrenoceptor blockade exerted by carvedilol imposes these beneficial hemodynamic effects. Carvedilol is a nonselective β-adrenoceptor antagonist, devoid of intrinsic sympathomimetic activity and possessing selective α<inf>1</inf> adrenoceptor-blocking activity, although this is considerably weaker than its β-adrenoceptor antagonistic activity. One isomer [S (-)-carvedilol] contains both the β-and α-adrenoceptor activity, whereas R(+)-carvedilol is only a weak alpha blocker. Carvedilol is produced as the racemate. The hemodynamic profile is in accordance with that to be expected from the combination of beta and alpha blockade. © 1993 S. Karger AG, Basel.
Original languageEnglish
Pages (from-to)19-23
JournalCardiology
Volume82
DOIs
Publication statusPublished - 1993
Externally publishedYes

Fingerprint

Dive into the research topics of 'Pharmacodynamic profile of carvedilol'. Together they form a unique fingerprint.

Cite this